Digidrotaxisterol

When ATH:
A11CC02

Characteristic.

Colourless crystals or a white crystalline powder. Practically insoluble in water, soluble in alcohol.

Pharmacological action.
D-vitamin-like, regulating calcium-phosphorus metabolism.

Application.

Inadequate secretion of parathyroid hormone: gipoparatireoz (autoimmune, postoperative, After treatment with radioactive iodine, traumatic, sarcoidosis or tuberculosis, neoplastic); functional hypoparathyroidism (inadequate secretion of PTH in response to hypocalcemia): in newborn, born to mothers, suffering from hypoparathyroidism; idiopathic neonatal hypocalcaemia; gipomagniemiya (malabsorption, vomiting and diarrhea, celiac disease, diabetes, acute pancreatitis, alcoholism); Vitamin D deficiency (nutritional deficiency, lack of UV rays, malabsorption, celiac disease, Short bowel syndrome, chronic pancreatitis, sprue); peripheral resistance parathyroid hormone: psevdogipoparatireoz (Albright syndrome); chronic renal failure (renal osteodystrophy); hypocalcemia iatrogenic nature: giperfosfatemiя (incl. food origin); the appointment of large doses of EDTA, Mithramycin, actinomycin, neomycin, ʙifosfonatov, thiazide diuretics, long-term use of laxatives, phenobarbital and other anticonvulsants, overdose of calcitonin; massive blood transfusion citrate, surgery under cardiopulmonary bypass.

Contraindications.

Hypersensitivity, hypercalcemia.

Pregnancy and breast-feeding.

When pregnancy is possible, if the effect of therapy outweighs the potential risk to the fetus (adequate and well-controlled studies on the use during pregnancy has not been).

Category actions result in FDA - C. (The study of reproduction in animals has revealed adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not held, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk.)

At the time of treatment should stop breastfeeding.

Side effects.

Paleness, headache, dizziness, weakness, heartbeat, thirst, dyspeptic disorders (anorexia, nausea, vomiting, diarrhea), pain in the right upper quadrant, due to the contraction of the gallbladder, impairment of renal function, kardioskleroz, fibrosis, nephrosclerosis (prolonged use).

Cooperation.

The rationale is to combine with calcium. Incompatible with other drugs of vitamin D. Thiazide diuretics promote the development of hypercalcemia. Not recommended combination with fenoterol.

Overdose.

Symptoms: increased side effects, related hypercalcemia. Occurrence of ataxia, amnesias, Disorientation, gallyutsinatsii, syncope, gipotonii, hypercalcemic coma.

Treatment: the immediate withdrawal of the drug, bed rest, excessive drinking, a diet low in calcium, appointment of loop diuretics and laxatives, in / in a saline solution, corticosteroids, tsitratov, sulphates, Phosphates, EDTA, Mithramycin; possible hemodialysis.

Dosing and Administration.

Inside. Dose selected individually, depending on the severity of hypocalcemia, and is 0.8-2.4 mg/day.

Precautions.

For the prevention of hypercalcemia requires regular monitoring of calcium and phosphorus in the blood and urine. We recommend that you follow a diet high in calcium and low in food-phosphorus. In patients with hypothyroidism, receiving treatment with thyroid hormones and receiving digidrotahisterol, undo the last should be done with caution because of the risk of hypercalcemia.